Q: What are the details of the nationwide recall on compounded tirzepatide weight-loss injections?

What was recalled, and what to do with a matching vial

A:Apothecary Pharma recalled 22 vials of compounded tirzepatide, distributed nationwide, because their sterility cannot be assured, and the FDA rated the recall Class II.¹ A compounded version of a drug is a customized medication created by a licensed pharmacist who alters or combines ingredients to meet the specific medical needs of a patient, and it is not the same as a generic medication.²

The recall began September 24, 2026, and was reported in October. The American Med Spa Association (AmSpa) published the details on October 22. Eli Lilly's Mounjaro and Zepbound, the brand-name tirzepatide drugs, are unaffected.¹

Each vial carries a national drug code (NDC), the product's federal identifier, and a lot number. The recalled tirzepatide is 18 mg/mL in 4 mL multidose vials, NDC 85091-001-18, lots AP-202622 through AP-202625, plus AP-202627 through AP-202644. The recalled NAD+ injection is lot AP-202647, at 200 mg/mL in a single 6 mL vial, NDC 85091-011-06.¹

WSOC-TV, a Charlotte television station citing USA Today, reported that the FDA raised the recall to Class II on October 10. Class II means patients could face "temporary or medically reversible adverse health consequences." NewsNation reported that no illnesses had been linked to the recall at that time.^3,4

The FDA had warned the same facility on December 1, 2025, citing serious deficiencies in sterile drug production. Lohud, a Gannett newspaper, reports that anyone holding a matching vial should contact their prescriber before using it, and a patient treated at a med spa should call the practice as a first step.^5,6 For more about what the FDA has found at other compounders and how a practice can track which patient got which lot, see our compounded injectables review.